Prostate cancer
Conditions
Interventions
MMR expression deletion group:N/A
Normal MMR expression group:N/A
Sponsors
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed prostate adenocarcinoma; 2. Prostate cancer tissue can be obtained for immunohistochemical staining of MLH1, MSH2, MSH6 and PMS2 MMR proteins; 3. Confirm the existence of distant metastasis by bone scan or PET-CT; 4. Received standardized systemic treatment including endocrine therapy and chemotherapy.
Exclusion criteria
Exclusion criteria: 1. Patients with life expectancy less than 1 year; 2. Patients with other tumor diseases; 3. Prostate cancer with other pathological types other than adenocarcinoma; 4. Patients who have received immunosuppressive therapy or have immune deficiency diseases; 5. Patients with severe liver function damage (Child-Pugh C); 6. Patients with severe renal function injury requiring long-term dialysis treatment; 7. Patients with severe myelosuppression and severe neutropenia; 8. Participate in other clinical studies from 30 days before enrollment to the completion of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progress-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Proportion of Patients With PSA Complete Response;Clinial stage;Pathological grade; | — |
Countries
China
Contacts
Public ContactChunguang Yang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed